Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announced that it has been awarded two grants totalling € 3.8M from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively ...